induct
antigen
specif
memori
cell
vivo
import
new
vaccin
infecti
diseas
present
studi
aim
evalu
immun
respons
peptidespecif
cell
induc
hlaa
restrict
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
epitop
plu
cpg
oligodeoxynucleotid
cpg
odn
polyi
c
adjuv
furthermor
gener
distribut
phenotyp
longlast
peptidespecif
memori
cell
assess
elisa
elispot
flow
cytometri
result
show
antigen
specif
cell
elicit
hlaa
restrict
sarscov
epitop
furthermor
frequenc
peptidespecif
cell
dramat
increas
prime
boost
immun
peptid
plu
cpg
odn
wherea
slight
enhanc
induc
follow
boost
vaccin
peptid
plu
polyi
c
sarscov
peptidespecif
cell
distribut
throughout
lymphoid
nonlymphoid
tissu
result
also
demonstr
hlaa
restrict
peptidespecif
cell
induc
peptid
plu
cpg
odn
carri
memori
cell
phenotyp
possess
longterm
surviv
abil
vivo
taken
togeth
result
impli
hlaa
restrict
sarscov
epitop
plu
cpg
odn
might
superior
candid
sar
vaccin
sever
acut
respiratori
syndrom
sar
lifethreaten
infecti
diseas
caus
novel
coronaviru
name
sarscov
although
first
sar
epidem
success
control
still
remain
potenti
threat
human
be
variabl
sarscov
possibl
reintroduct
sarscov
human
anim
risk
escap
laboratori
furthermor
evid
prove
humor
immun
respons
sar
recov
patient
decreas
timedepend
manner
previou
result
show
cellular
immun
respons
attenu
recov
individu
date
effect
drug
prevent
treat
sar
know
vaccin
econom
effect
strategi
protect
bodi
infecti
diseas
recent
epitop
vaccin
mainli
contain
protect
epitop
without
patholog
peptid
consid
alternaabbrevi
sar
sever
acut
respiratori
syndrom
sarscov
sarsassoci
coronaviru
cpg
odn
cpg
oligodeoxynucleotid
tlr
tolllik
receptor
correspond
author
tel
fax
email
address
changyou
wu
yahoocom
c
wu
tive
approach
regard
sarscov
mani
cell
epitop
identifi
us
group
previou
studi
identifi
five
epitop
cell
hlaa
transgen
mous
dna
prime
peptid
boost
strategi
howev
poor
immunogen
emphas
major
unmet
need
immunostimulatori
adjuv
safe
boost
cellular
immun
respons
vaccin
adjuv
mimic
tolllik
receptor
tlr
ligand
advantag
capabl
elicit
posit
effect
across
entir
spectrum
innat
adapt
immun
previou
data
demonstr
addit
effect
cpg
oligodeoxynucleotid
cpg
odn
pika
adjuv
augment
immun
respons
hbsag
vaccin
cpg
polyi
c
ligand
respect
activ
antigenpres
cell
lead
cell
prime
acquir
immun
present
studi
evalu
cellular
immun
respons
induc
hlaa
restrict
sarscov
epitop
examin
whether
tlr
ligand
cpg
polyi
c
adjuv
lead
enhanc
cell
activ
hlaa
restrict
sar
peptid
result
demonstr
antigen
specif
cell
elicit
hlaa
restrict
sarscov
epitop
first
time
found
cpg
polyi
c
differ
abil
prime
cell
boost
memori
cell
data
provid
evid
effici
ctl
product
mice
vaccin
hlaa
restrict
sar
peptid
plu
cpg
obvious
enhanc
furthermor
major
longlast
cell
specif
sar
protein
vivo
effector
memori
phenotyp
hlaa
b
transgen
tg
mice
gift
prof
yz
wu
institut
immunolog
third
militari
medic
univers
chongq
china
tg
mice
bred
pathogenfre
facil
cell
surfac
hlaa
express
assess
flow
cytometri
use
fitclabel
antihuman
ab
bd
bioscienc
pharmingen
experiment
purpos
six
eight
weekold
femal
mice
use
experi
perform
accord
guidelin
institut
anim
committe
tmmu
cpg
odn
synthes
sangon
crop
shanghai
china
polyi
c
purchas
sigma
usa
kind
gift
pharmaceut
corp
st
paul
usa
hlaa
restrict
peptid
deriv
strain
sarscov
genbank
access
synthes
sangon
crop
shanghai
china
five
peptid
name
vvflhvtyv
ilpdplkpt
rlnevaknl
vlndilsrl
klpddfmgcv
identifi
us
group
peptid
purifi
revers
phase
hplc
confirm
mass
spectrometri
dissolv
pb
mgml
store
aliquot
c
pool
hlaa
restrict
peptid
g
inject
subcutan
either
alon
mixtur
solubl
cpg
g
polyi
c
g
nmol
respect
base
tail
hlaa
b
tg
mice
one
week
later
mice
boost
regimen
pb
administr
alon
control
three
mice
use
group
media
purchas
gibco
supplement
heatinactiv
fc
uml
penicillin
gml
streptomycin
purifi
antimous
isotyp
control
ab
purchas
bd
bioscienc
pharmingen
mice
sacrif
lymph
node
poplit
fossa
groin
mesenteri
spleen
lung
individu
mous
harvest
month
boost
vaccin
singlecel
suspens
prepar
plate
triplic
round
bottom
plate
l
per
well
gml
final
concentr
plu
ml
ad
cultur
experi
cultur
absenc
peptid
neg
control
three
day
incub
cellfre
cultur
supernat
collect
level
detect
specif
elisa
kit
bd
pharmingen
accord
manufactur
protocol
assay
perform
use
mous
elispot
set
bd
pharmingen
accord
instruct
provid
manufactur
briefli
spleen
singlecel
suspens
vaccin
mice
prepar
plate
micro
plate
millipor
precoat
antibodi
overnight
c
block
contain
fb
cell
incub
h
presenc
absenc
plu
c
co
well
wash
incub
biotinyl
label
antimous
antibodi
h
room
temperatur
wash
well
incub
streptavidin
conjug
horseradish
peroxidas
h
room
temperatur
well
extens
wash
develop
aec
substrat
solut
dri
well
count
tcl
elispot
reader
usa
singlecel
suspens
lymph
node
spleen
lung
vaccin
mice
cocultur
without
plu
h
c
co
brefeldin
gml
sigma
ad
last
h
incub
cell
wash
fix
paraformaldehyd
permeabil
pb
buffer
contain
saponin
sigma
bsa
nan
overnight
c
cell
stain
conjug
mab
surfac
marker
intracellular
cytokin
min
c
dark
cell
acquir
flow
cytomet
calibur
bd
data
analyz
program
flowjo
version
tree
star
inc
usa
isotyp
control
includ
stain
statist
evalu
differ
mean
experiment
group
perform
analysi
varianc
nonparametr
twotail
ttest
valu
p
consid
signific
express
ifnfrom
hlaa
restrict
peptidespecif
cell
enhanc
vari
degre
cpg
odn
polyi
c
assess
cellular
immun
respons
elicit
vaccin
hlaa
restrict
sar
peptid
combin
cpg
odn
polyi
c
respect
hlaa
b
tg
mice
randomli
divid
five
group
accept
immun
prime
boost
vaccin
mice
sacrif
cell
prepar
lymph
node
spleen
lung
cell
stimul
without
cognat
peptid
plu
detect
hlaa
restrict
peptidespecif
immun
respons
level
cellfre
cultur
supernat
determin
elisa
result
reveal
almost
undetect
lymphocyt
cultur
medium
alon
pb
group
follow
prime
immun
modest
product
spleen
lymph
node
lymphocyt
peptid
alon
immun
mice
p
howev
product
markedli
enhanc
organ
peptid
plu
cpg
odn
immun
mice
spleen
lymph
node
p
lung
p
howev
cpg
odn
express
prime
boost
immun
peptid
plu
differ
adjuv
hlaa
tg
mice
vaccin
differ
agent
similar
manner
describ
materi
method
fresh
isol
lymphocyt
spleen
lymph
node
lung
cultur
gml
cognat
peptid
plu
gml
medium
alon
control
product
supernat
prime
boost
immun
cultur
set
triplic
symbol
repres
one
data
point
one
mous
p
p
p
ns
p
polyi
c
promot
product
first
vaccin
shown
fig
diamond
symbol
repres
level
lymphocyt
boost
mice
interestingli
product
spleen
boost
mice
much
stronger
one
prime
mice
addit
modest
increas
spleen
peptid
plu
polyi
c
boost
mice
though
level
lymph
node
lung
almost
undetect
taken
togeth
data
indic
system
strike
cytokin
product
induc
tg
mice
follow
hlaa
restrict
peptid
plu
cpg
odn
vaccin
furthermor
result
provid
evid
cpg
odn
polyi
c
potent
activ
innat
immun
respons
mayb
differ
abil
prime
cell
induc
memori
cell
detect
product
total
lymphocyt
elisa
furthermor
confirm
distinct
abil
cpg
odn
polyi
c
experi
next
analyz
frequenc
cell
singl
cell
level
elispot
assay
shown
fig
prime
immun
hlaa
restrict
peptid
alon
peptid
plu
cpg
odn
cell
spleen
produc
averag
spot
cell
spot
cell
respect
antigen
specif
cell
exhibit
increas
presenc
cpg
odn
adjuv
howev
almost
cell
induc
peptid
plu
polyi
c
group
compar
prime
vaccin
frequenc
cell
spleen
boost
immun
mice
dramat
increas
spot
per
cell
peptid
plu
cpg
odn
group
meanwhil
spot
spot
per
cell
show
respect
peptid
plu
polyi
c
group
peptid
plu
group
result
consist
data
elisa
confirm
effect
cpg
odn
polyi
c
adjuv
improv
cellular
immun
respons
previou
studi
shown
peptidespecif
cell
induc
belong
cell
cell
hlaa
restrict
peptid
could
act
stimul
elicit
strike
peptidespecif
ctl
respons
present
studi
still
found
cytokin
product
cell
follow
cognat
peptid
stimul
consist
previou
result
data
shown
shown
fig
cell
gate
prime
immun
product
detect
simultan
result
show
first
immun
hlaa
restrict
peptidespecif
ctl
could
produc
time
peptid
alon
peptid
plu
cpg
odn
group
fig
furthermor
overal
respons
obtain
coinject
cpg
odn
consist
stronger
ctl
yield
obtain
use
peptid
alon
interestingli
follow
boost
immun
percentag
cytokin
posit
cell
spleen
dramat
increas
peptid
plu
cpg
odn
group
fig
agreement
fig
percentag
splenic
peptidespecif
ctl
elicit
peptid
alon
boost
mice
gener
lower
one
coinject
cpg
odn
group
also
show
twofold
enhanc
cytokineproduc
cell
mice
boost
compar
first
immun
modest
cytokineposit
cell
induc
spleen
peptid
combin
polyi
c
boost
mice
conform
previou
result
elisa
elispot
fig
analysi
relationship
produc
cell
found
cell
express
simultan
prime
boost
mice
small
subset
cell
express
either
alon
fig
impli
peptidespecif
ctl
induc
model
strong
abil
secret
variou
cytokin
may
polyfunct
lymphocyt
besid
accord
express
peptidespecif
ctl
could
divid
three
distinct
subpopul
includ
cell
cell
cell
experi
fig
shown
result
elisa
elispot
fac
three
differ
assay
distinct
aspect
coincid
demonstr
cpg
odn
significantli
addit
adjuv
effect
could
augment
cellular
immun
respons
induc
hlaa
restrict
peptid
sar
protein
ascertain
whether
distribut
hlaa
restrict
peptidespecif
cell
distinct
differ
organ
detect
percentag
produc
cell
lymph
node
spleen
lung
shown
fig
cell
cell
could
induc
lymph
tissu
lymph
node
spleen
nonlymph
tissu
lung
indic
peptid
plu
adjuv
could
induc
system
cellular
immun
respons
suggest
ctl
elicit
vivo
may
effect
function
protect
bodi
infect
character
phenotyp
hlaa
restrict
peptidespecif
cell
basi
abil
produc
splenocyt
peptid
alon
peptid
plu
cpg
odn
immun
tg
mice
stimul
cognat
peptid
h
incub
cell
harvest
wash
stain
cellsurfac
marker
includ
marker
memori
cell
mice
effectorcentr
memori
subset
marker
cell
first
gate
cell
phenotyp
cell
analyz
shown
fig
cell
spleen
express
peptid
alon
peptid
plu
cpg
odn
group
accord
express
approxim
cell
cell
repres
effector
memori
cell
variabl
fraction
cell
cell
consid
typic
central
memori
cell
thu
basi
produc
cell
popul
peptidespecif
cell
characterist
memori
cell
identifi
present
studi
cell
might
inde
belong
intermedi
subset
readi
conscript
effector
popul
reinfect
experi
evalu
peptidespecif
ctl
immun
respons
prime
boost
vaccin
know
antigenspecif
memori
cell
play
import
role
clear
viru
could
induc
vivo
fast
specif
manner
interest
whether
long
surviv
memori
cell
could
elicit
follow
peptid
plu
cpg
odn
vaccin
therefor
extend
studi
character
sar
hlaa
restrict
peptidespecif
longpersist
memori
cell
respons
boost
immun
accord
data
elisa
elispot
found
mice
immun
peptid
combin
cpg
odn
still
maintain
high
level
cellular
immun
respons
splenocyt
though
pass
sinc
second
vaccin
shown
fig
splenocyt
stimul
specif
peptid
vitro
secret
higher
level
control
p
base
product
frequenc
peptidespecif
cell
spot
cell
result
suggest
peptidespecif
cell
induc
peptid
plu
cpg
odn
vaccin
longtim
life
span
vivo
compar
previou
data
boost
immun
though
degre
cellular
immun
respons
decreas
part
still
believ
peptidespecif
memori
cell
long
live
vivo
quickli
conscript
effector
popul
protect
bodi
reinfect
furthermor
detect
percentag
cytokin
produc
persist
peptidespecif
memori
cell
result
show
produc
cell
still
could
detect
spleen
though
month
past
sinc
boost
vaccin
percentag
mean
valu
cell
cell
mean
valu
stimul
splenocyt
fold
fold
higher
cell
cultur
medium
alon
respect
fig
besid
base
product
phenotyp
longliv
peptidespecif
cell
character
surfac
marker
shown
fig
major
cell
carri
memori
cell
phenotyp
taken
togeth
result
provid
evid
longlast
peptidespecif
memori
cell
induc
sar
hlaa
restrict
peptid
plu
cpg
odn
abil
produc
time
addit
result
consist
previou
report
show
major
longtim
surviv
cell
specif
sar
hlaa
restrict
peptid
vivo
effector
memori
cell
previou
studi
evalu
cellular
immun
respons
hlaa
tg
mice
prime
intramuscularli
sar
dna
boost
subcutan
hlaa
restrict
peptid
previou
data
show
antigen
specif
memori
cell
induc
dna
prime
peptid
boost
strategi
consid
poor
immunogen
stabil
oligopeptid
vivo
focus
immun
respons
peptidespecif
cell
induc
hlaa
restrict
sarscov
epitop
vaccin
interestingli
found
antigen
specif
cell
elicit
hlaa
restrict
sarscov
epitop
might
possess
stabl
chemic
physic
properti
vivo
memori
phenotyp
could
exist
long
time
absenc
cognat
peptid
data
provid
credibl
evid
direct
applic
epitop
sar
vaccin
design
current
adjuv
approv
fda
use
clinic
alum
although
aluminum
abl
induc
good
respons
weak
capac
stimul
strong
cellular
immun
respons
import
protect
mani
pathogen
adjuv
usual
use
enhanc
immunogen
vaccin
requir
promot
humor
immun
respons
also
cellular
immun
respons
molecular
mechan
underli
adjuv
activ
poorli
understood
long
time
field
rapidli
evolv
sinc
discoveri
tlr
famili
protein
correspond
innat
ligand
cpg
odn
polyi
c
specif
ligand
tlr
critic
link
innat
adapt
immun
previou
report
studi
cpg
odn
pika
adjuv
could
enhanc
hb
agspecif
cell
respons
regard
sar
new
report
prove
coadministr
inactiv
sarscov
vaccin
pika
adjuv
could
induc
much
higher
neutral
activ
anim
model
howev
relat
report
ascertain
adjuv
superior
hlaa
restrict
sar
peptid
vaccin
therefor
present
studi
evalu
effici
synthet
cpg
odn
polyi
c
adjuv
combin
cell
epitop
vaccin
sar
immun
hlaa
tg
mice
cpg
odn
polyi
c
adjuv
identifi
specif
ligand
tlr
potent
activ
innat
immun
respons
activ
dendrit
cell
dc
matur
inflammatori
cytokin
secret
induc
increas
cross
talk
innat
adapt
immun
system
therebi
drive
expans
ctl
destroy
viru
infect
target
cell
result
show
cell
respons
cpg
odn
superior
polyi
c
may
due
sever
reason
first
differ
tlr
even
differ
ligand
tlr
differ
substanti
abil
induc
product
peptidespecif
primari
memori
cell
respons
report
cpg
odn
potent
induc
direct
differenti
cell
type
effector
mccluski
et
al
compar
efficaci
cpg
odn
topic
immunoprophylaxi
immunotherapi
vagin
herp
simplex
viru
type
infect
mice
found
efficaci
hsv
infect
observ
cpg
odn
less
even
repeat
administr
furthermor
evid
rothenfuss
et
al
prove
two
distinct
type
cpg
odn
identifi
differ
capac
stimul
cell
cpgb
seem
superior
prime
cell
respons
cpga
select
enhanc
memori
cell
respons
know
cpg
odn
ligand
signal
via
pathway
lead
activ
nfb
critic
transcript
factor
induct
inflammatori
cytokin
addit
signal
also
induc
type
interferon
via
pathway
recogn
polyi
c
use
pathway
recogn
use
tirap
tirf
therefor
clear
differ
tlr
signal
profoundli
affect
innat
immun
respons
relat
cascad
activ
adapt
immun
respons
furthermor
differ
respons
dc
differ
tlr
ligand
express
plasmacytoid
nonplasmacytoid
dc
whether
spleen
thymu
grown
vitro
bone
marrow
progenitor
respond
cpg
mous
spleen
plasmacytoid
dc
also
express
especi
strike
fact
splenic
dc
express
mrna
respond
vitro
contrast
dc
display
highest
express
messag
appear
absent
plasmacytoid
dc
howev
situat
somewhat
differ
human
human
blood
contain
least
two
distinct
dc
type
dc
plasmacytoid
dc
well
monocyt
precursor
modc
present
result
also
case
human
possibl
use
cpg
odn
sar
epitop
vaccin
human
would
prove
superior
polyi
c
howev
would
need
test
clinic
studi
final
detail
dose
respons
analys
also
requir
allow
distinct
quantit
qualit
effect
tlr
ligat
accord
previou
report
respons
optim
g
solubl
cpg
odn
coinject
per
anim
also
decreas
higher
dose
phenomenon
found
polyi
c
optim
ctl
respons
obtain
g
whether
declin
occur
function
exhaust
cell
overload
system
antigen
remain
investig
evid
support
previou
find
presenc
cpg
odn
cell
expans
lead
increas
express
report
associ
cytolyt
activ
peptidespecif
cell
suggest
cpg
odn
mayb
increas
frequenc
peptidespecif
cell
also
affect
phenotyp
therefor
focus
phenotyp
peptidespecif
memori
cell
detect
express
surfac
marker
memori
cell
mice
express
consid
standard
distinguish
central
memori
cell
effector
memori
cell
detect
express
cell
mice
immun
peptid
absenc
presenc
cpg
odn
basi
product
show
percentag
peptidespecif
cell
significantli
enhanc
cpg
odn
meanwhil
antigenspecif
cell
carri
phenotyp
howev
signific
differ
found
express
peptid
alon
peptid
plu
cpg
odn
group
result
indic
cpg
odn
increas
quantiti
peptidespecif
cell
affect
qualiti
antigen
specif
memori
cell
addit
challeng
adjuv
usag
develop
safe
adjuv
stimul
antibodi
cellmedi
immun
present
studi
humor
immun
respons
observ
peptid
belong
hlaa
restrict
antigen
stimul
cell
howev
previou
data
demonstr
significantli
larg
amount
antihb
ab
sera
obtain
mice
immun
hbsag
combin
cpg
odn
suggest
augment
cellular
immun
respons
also
remark
effect
enhanc
humor
immun
respons
efficaci
adjuv
induc
humor
immun
respons
sar
vaccin
also
import
undoubtedli
paid
attent
ongo
research
plan
know
induct
surviv
immun
memori
cell
vivo
lay
foundat
develop
vaccin
excit
us
data
show
peptid
specif
cell
longliv
memori
cell
peptid
combin
cpg
immun
mice
although
frequenc
percentag
antigenspecif
cell
lightli
decreas
consider
level
product
fig
furthermor
follow
cognat
peptid
stimul
vitro
longlast
antigenspecif
memori
cell
capac
produc
time
fig
say
word
one
hallmark
success
vaccin
induct
strong
persist
memori
cell
respons
therefor
result
provid
us
shine
perspect
use
clinic
vaccin
develop
conclus
cpg
odn
augment
sar
peptid
specif
cell
immun
respons
antigenspecif
cell
carri
memori
cell
phenotyp
exist
long
time
vivo
vaccin
adjuv
mimic
tlr
ligand
advantag
capabl
elicit
posit
effect
across
entir
spectrum
innat
adapt
immun
therefor
result
provid
novel
inform
vaccin
design
ongo
clinic
trial
provid
insight
activ
cpg
odn
immun
adjuv
epitop
vaccin
sar
